1. 2009
2. Cyhoeddwyd

   Impact of the abolition of the prescription charge in Wales.

   Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009, t. O41.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   The economics of evergreening.

   Hughes, D. & Hughes, D. A., 1 Ion 2009.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. 2008
5. Cyhoeddwyd

   Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens

   Hughes, D. & Hughes, D. A., 1 Rhag 2008, Yn: British Journal of Clinical Pharmacology. 65, 6, t. 871-878

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   Impact of the abolition of the prescription charge in Wales

   Hughes, D. & Hughes, D. A., 1 Tach 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

7. Cyhoeddwyd

   Methodological Issues in the literature on costs of non-compliance in chronic diseases.

   Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008, Yn: Value in Health. 11, 6, t. A571-A572

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Methodological issues in the literature on costs of non-compliance in chronic diseases

   Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

9. Cyhoeddwyd

   The all wales medicines strategy group: assessments and appraisals

   Hughes, D. & Hughes, D. A., 1 Tach 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

10. Cyhoeddwyd

    Medicines concordance and game theory.

    Hughes, D. & Hughes, D. A., 1 Hyd 2008, Yn: British Journal of Clinical Pharmacology. 66, 4, t. 577

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Economic considerations for pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Meh 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

12. Cyhoeddwyd

    Costs of non-compliance to antipsychotic medications among patients with schizophrenia.

    Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Mai 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

13. Cyhoeddwyd

    The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

14. Cyhoeddwyd

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

15. Cyhoeddwyd

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

16. Cyhoeddwyd

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Maw 2008

    Allbwn ymchwil: Ffurf annhestunol › Safe Gwe / Cyhoeddiad Gwe

18. Cyhoeddwyd

    Statistical comments are unfounded.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Maw 2008, Yn: Value in Health. 11, 2, t. 346

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

19. Cyhoeddwyd

    The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

    Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Maw 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

20. Cyhoeddwyd

    Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Chwef 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

21. Cyhoeddwyd

    From efficacy to cost-effectiveness: Impact of patient compliance

    Hughes, D. & Hughes, D. A., 1 Chwef 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

22. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

23. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

24. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

25. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

26. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

27. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

28. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

29. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

30. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

31. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

32. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

33. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

34. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

35. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

36. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

37. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

38. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

39. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

40. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

41. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

42. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

43. Cyhoeddwyd

    Charitable contributions to funding cancer services for children and young people in England and Wales

    Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2008, Yn: Journal of Child Health Care. 12, 2, t. 156-168

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

44. Cyhoeddwyd

    Chiral chromatography: Costs of chiral switching.

    Hughes, D. & Hughes, D. A., 1 Ion 2008, Yn: Pharmaceutical Journal. 281, t. 213

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

45. Cyhoeddwyd

    Cost-effectiveness considerations in pharmacogenetics.

    Hughes, D. & Hughes, D. A., 1 Ion 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

46. Cyhoeddwyd

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

47. Cyhoeddwyd

    Effects of the abolition of prescription charges in Wales: a preliminary analysis.

    Hughes, D., Cohen, D., Alam, M. F., Hughes, D. A., Dunstan, F. & Routledge, P., 1 Ion 2008, Yn: International Journal of Pharmacy Practice. 16, Supplement 1, t. A39

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

48. Cyhoeddwyd

    Integrating compliance and persistence in health economics models

    Hughes, D. & Hughes, D. A., 1 Ion 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

49. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

50. Cyhoeddwyd

    Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

    Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T., Morgan, R., Woods, R. T., Burholt, V., Edwards, R. T., Reeves, C. & Yeo, S. T., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

51. Cyhoeddwyd

    Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness: Evidence Tables.

    Hughes, D., Linck, P. G., Windle, G., Linck, P., Morgan, R., Hughes, D. A., Burholt, V., Reeves, C., Yeo, S. T., Woods, R. T., Edwards, R. T. & Russell, I. T., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

52. Cyhoeddwyd

    Understanding medication compliance and persistence from an economics perspective

    Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Ion 2008, Yn: Value in Health. 11, 4, t. 600-610

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

53. 2007
54. Cyhoeddwyd

    A Global Survey of Antibiotic Leftovers in the Outpatient Setting.

    Hughes, D., Kardas, P., Pechere, J. C., Hughes, D. A. & Cornaglia, G., 1 Rhag 2007, Yn: International Journal of Antimicrobial Agents. 30, 6, t. 530-536

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

55. Cyhoeddwyd

    Public meetings of the NICE appraisals committee

    Hughes, D. & Hughes, D. A., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

56. Cyhoeddwyd

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

57. Cyhoeddwyd

    Folate Augmentation of Treatment – Evaluation for Depression (FolATED): protocol of a randomised controlled trial.

    Russell, I. T., Slegg, G. P., Roberts, S. H., Bedson, E., Hughes, D., Lloyd, K., Moat, S., Pirmohamed, M., Slegg, G., Tranter, R., Whitaker, R., Wilkinson, C. & Russell, I., 15 Tach 2007, Yn: BMC Psychiatry. 7, 1, t. 65

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

58. Cyhoeddwyd

    Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Tach 2007, Yn: Value in Health. 10, 6, t. 498-509

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

59. Cyhoeddwyd

    Orphan drug treatments: economic considerations

    Hughes, D. & Hughes, D. A., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

60. Cyhoeddwyd

    Population pharmacokinetics of warfarin: Intermin analysis of the Liverpool pharmacogenetic prospective cohort study

    Hughes, D., Matthews, I., Aarons, L., Al-Zubiedi, S., Hatch, E., Lane, S., Williamson, P., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

61. Cyhoeddwyd

    The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

    Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

62. Cyhoeddwyd

    Feasibility, validity and reliability of the Welsh version of the EQ-5D health status questionnaire.

    Hughes, D. & Hughes, D. A., 1 Hyd 2007, Yn: Quality of Life Research. 16, 8, t. 1419-1423

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

63. Cyhoeddwyd

    Interventions that enhance medication compliance and persistence: Theoretical grounding, and economic assessment

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F., Elliott, R. & Cowell, W., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

64. Cyhoeddwyd

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

65. Cyhoeddwyd

    The assessment, determinants & economics of medication compliance & persistence

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

66. Cyhoeddwyd

    Impact of the abolition of prescription charges in Wales: a multi-level modelling approach with application to time series dispensed rate data

    Hughes, D., Alam, F., Myles, S., Hughes, D. A., Dunstan, F., Routledge, P. & Cohen, D., 1 Medi 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

67. Cyhoeddwyd

    A prototype agent-based model of antimalarial drug compliance

    Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

68. Cyhoeddwyd

    Cost of non-compliance and non-persistence with medications for diabetes mellitus

    Hughes, D., Salas, M., Hughes, D. A., Lebmeier, M. & Vardeva, K., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

69. Cyhoeddwyd

    Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

70. Cyhoeddwyd

    Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Awst 2007, Yn: Clinical Pharmacology and Therapeutics. 82, 2, t. 123-127

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

71. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Gorff 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

72. Cyhoeddwyd

    Adherence with HAART: pharmacoeconomic considerations

    Hughes, D. & Hughes, D. A., 1 Meh 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

73. Cyhoeddwyd

    A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

    Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

74. Cyhoeddwyd

    Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

    Hughes, D. & Hughes, D. A., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

75. Cyhoeddwyd

    Biological agents for the management of Crohn's disease in adults: a systematic review, meta-analysis and multiple treatment comparison

    Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

76. Cyhoeddwyd

    Factors influencing user choices to visit either general practitioners or community pharmacists for minor ailments – a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M., Lisles, C. & Hood, K., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

77. Cyhoeddwyd

    Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

    Hughes, D. & Hughes, D. A., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

78. Cyhoeddwyd

    Quantitative risk-benefit analysis

    Hughes, D. & Hughes, D. A., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

79. Cyhoeddwyd

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

80. Cyhoeddwyd

    Adverse drug reactions: analysis by regulatory authorities and by economists

    Hughes, D. & Hughes, D. A., 1 Ebr 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

81. Cyhoeddwyd

    Parenting programme for parents of children at risk of developing conduct disorder: cost effectiveness analysis.

    Bywater, T. J., Hutchings, J. M., Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 31 Maw 2007, Yn: British Medical Journal. 334, 7595, t. 682-685

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

82. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

83. Cyhoeddwyd

    Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

    Hughes, D., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

84. Cyhoeddwyd

    Economic evaluation of steroid injections (methylprednisolone) in the treatment of Morton's neuroma: patient-blind randomised trial

    Hughes, D., Thomson, C., Beggs, I., Martin, D., McCaldin, D., Russell, D., Edwards, R. T., Hughes, D. A., Yeo, S. T., Russell, I. T. & Gibson, T. N., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

85. Cyhoeddwyd

    Falls and hip-fractures: A cost-effectiveness analysis of risk assessment and interventions for community-dwelling older people

    Hughes, D., Gwynne, D., Hughes, D. A. & Edwards, R. T., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

86. Cyhoeddwyd

    Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

    Hughes, D., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

87. Cyhoeddwyd

    Non-compliance with antibiotic therapy for acute community infections: A global survey.

    Hughes, D., Pechere, J. C., Hughes, D. A., Kardas, P. & Cornaglia, G., 1 Maw 2007, Yn: International Journal of Antimicrobial Agents. 29, 3, t. 245-253

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

88. Cyhoeddwyd

    Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer

    Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

89. Cyhoeddwyd

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

90. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

91. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

92. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

93. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

94. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

95. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

96. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

97. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

98. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

99. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

100. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

101. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Tipranavir (Aptivus).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

102. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

103. Cyhoeddwyd

     Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

     Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A171

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

104. Cyhoeddwyd

     Biological agents for the management of Crohn's disease in adults: A systematic review, meta-analysis and multiples treatment comparison

     Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A147

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

105. Cyhoeddwyd

     Factors influencing user choices to visit either general practitioners or community pharmacists for minor ailments – a discrete choice experiment

     Hughes, D., Hughes, D. A., Myles, S., Longo, M., Lisles, C. & Hood, K., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A23

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

106. Cyhoeddwyd

     Feasibility, validity, and reliability of the Welsh version of the EQ-5D health status questionnaire

     Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A189

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

107. Cyhoeddwyd

     Follow-up of cancer patients in primary care versus secondary care: systematic review.

     Hughes, D., Lewis, R., Neal, R., Williams, N., France, B., Wilkinson, C., Hendry, M., Russell, D., Hughes, D. A., Russell, I. T., Stuart, N. S. & Weller, D., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

108. Cyhoeddwyd

     Policy on ultra-orphan drugs.

     Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

109. Cyhoeddwyd

     Public health interventions to promote mental well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

     Hughes, D., Windle, G., Hughes, D. A., Linck, P., Morgan, R., Burholt, V., Edwards, R. T., Reeves, C., Yeo, S. T., Woods, R. T. & Russell, I. T., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

110. Cyhoeddwyd

     Warfarin pharmacogenetics: Economic considerations.

     Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Ion 2007, Yn: Pharmacoeconomics. 25, 11, t. 899-902

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

111. Cyhoeddwyd

     When drugs don't work - Economic assessment of enhancing compliance with interventions supported by electronic monitoring devices.

     Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Pharmacoeconomics. 25, 8, t. 621-635

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

112. 2006
113. Cyhoeddwyd

     Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

     Hughes, D. & Hughes, D. A., 1 Tach 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

114. Cyhoeddwyd

     Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

     Hughes, D. & Hughes, D. A., 1 Medi 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

115. Cyhoeddwyd

     Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

     Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

116. Cyhoeddwyd

     Prescription fee exemption research study

     Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Meh 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

117. Cyhoeddwyd

     Back to basics: what is the relationship between dose and duration of drug action?

     Hughes, D. & Hughes, D. A., 1 Mai 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

118. Cyhoeddwyd

     Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments

     Hughes, D. & Hughes, D. A., 1 Mai 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

119. Cyhoeddwyd

     Orphan drugs revisited: author's response.

     Hughes, D. & Hughes, D. A., 1 Mai 2006, Yn: Quarterly Journal of Medicine. 99, 5, t. 350-351

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

120. Cyhoeddwyd

     Health and economic outcomes: Why compliance matters

     Hughes, D. & Hughes, D. A., 1 Ebr 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

121. Cyhoeddwyd

     Physchiatrist prescribing preferences and attitudes toward promotion

     Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Ebr 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

122. Cyhoeddwyd

     Rationing of drugs for rare diseases

     Hughes, D. & Hughes, D. A., 1 Ebr 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

123. Cyhoeddwyd

     Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

     Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Maw 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

124. Cyhoeddwyd

     Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.

     Simpson, J. A., Hughes, D., Manyando, C., Bojang, K., Aarons, L., Winstanley, P., Edwards, G., Watkins, W. A. & Ward, S., 1 Maw 2006, Yn: British Journal of Clinical Pharmacology. 61, 3, t. 289-300

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

125. Cyhoeddwyd

     Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Chwef 2006, Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

126. Cyhoeddwyd

     Beyond registration: measuring the public health potential of new treatments for Malaria in Africa.

     Hughes, D., Lang, T., Hughes, D. A., Kanyok, T., Kengeya-Kayondo, J., Marsh, V., Haaland, A., Pirmohamed, M. & Winstanley, P., 1 Ion 2006, Yn: Lancet Infectious Diseases. 6, 1, t. 46-52

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

127. Cyhoeddwyd

     Health economic aspects of patient non-compliance

     Hughes, D., Hughes, D. A., Davies, M. (gol.) & Kermani, F. (gol.), 1 Ion 2006, Patient Compliance: Sweetening the Pill. 2006 gol. Gower Publishing, t. 23-40

     Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

128. Cyhoeddwyd

     Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

129. Cyhoeddwyd

     Improving Outcomes for People with Sarcoma: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

130. Cyhoeddwyd

     Less is more: Medicines that require less frequent administration improve adherence, but are they better?

     Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 3, t. 211-213

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

131. Cyhoeddwyd

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Ion 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

132. Cyhoeddwyd

     Rationing of drugs for rare diseases.

     Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 4, t. 315-316

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

133. 2005
134. Cyhoeddwyd

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 11 Tach 2005, Yn: Value in Health. 8, 6, t. A192

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

135. Cyhoeddwyd

     Drugs for exceptionally rare diseases: do they deserve special status for funding?

     Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

136. Cyhoeddwyd

     Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

     Hughes, D., Hughes, D. A. & Cowell, W., 1 Tach 2005.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

137. Cyhoeddwyd

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Tach 2005.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

138. Cyhoeddwyd

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Tach 2005.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

139. Cyhoeddwyd

     Trends and influences on use of antidiabetic drugs in England, 1992-2003.

     Walley, T., Hughes, D. & Kendall, H., 1 Tach 2005, Yn: Pharmacoepidemiology and Drug Safety. 14, 11, t. 769-773

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

140. Cyhoeddwyd

     Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.

     Hughes, D. & Hughes, D. A., 1 Gorff 2005, Yn: European Journal of Cancer. 41, 11, t. 1655

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

141. Cyhoeddwyd

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Gorff 2005.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

142. Cyhoeddwyd

     Empirical analysis of the relationship between dose and duration of drug action

     Hughes, D. & Hughes, D. A., 1 Meh 2005.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

143. Cyhoeddwyd

     Pharmacokinetics, patient compliance and pharmaeconomics

     Hughes, D. & Hughes, D. A., 1 Meh 2005.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

144. Cyhoeddwyd

     Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.

     Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Chwef 2005, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, t. 29-38

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

145. Cyhoeddwyd

     Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.

     Hughes, D., Hughes, D. A., Bodger, K., Bytzer, P., De Herdt, D. & Dubois, D., 1 Ion 2005, Yn: Pharmacoeconomics. 23, 10, t. 1031-1041

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

146. Cyhoeddwyd

     Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2005, 2005 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

147. Cyhoeddwyd

     Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Sweden.

     Hughes, D. & Hughes, D. A., 1 Ion 2005, 2005 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

148. Cyhoeddwyd

     Welsh Health Economics Network (WHEN): Scoping Report.

     Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

149. 2004
150. Cyhoeddwyd

     A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

     Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

151. Cyhoeddwyd

     Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease

     Hughes, D. & Hughes, D. A., 1 Tach 2004, Yn: Value in Health. 7, 6, t. 753

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

152. Cyhoeddwyd

     From efficacy to effectiveness and cost-effectiveness: modelling possibilities

     Hughes, D. & Hughes, D. A., 1 Tach 2004.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

153. Cyhoeddwyd

     HLA-B*5701 and abacavir hypersensitivity - Reply.

     Hughes, D., Hughes, D. A., Park, B. K. & Pirmohamed, M., 1 Tach 2004, Yn: Pharmacogenetics. 14, 11, t. 784

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

154. Cyhoeddwyd

     Economic evaluation of on-demand maintenance therapy with proton pump inhibitors in patients with symptomatic gastroesophageal reflux disease - a Monte-Carlo analysis for Italy

     Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Hyd 2004.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

155. Cyhoeddwyd

     The difference between effectiveness and efficacy of antimalarial drugs in Kenya.

     Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Medi 2004, Yn: Tropical Medicine and International Health. 9, 9, t. 967-974

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

156. Cyhoeddwyd

     Introduction to pharmaeconomics

     Hughes, D. & Hughes, D. A., 1 Gorff 2004.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

157. Cyhoeddwyd

     Pharmacoeconomic models that incorporate non-compliance

     Hughes, D. & Hughes, D. A., 1 Gorff 2004.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

158. Cyhoeddwyd

     Pharmacoeconomics appraisals by the all Wales medicines strategy group

     Hughes, D. & Hughes, D. A., 1 Gorff 2004.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

159. Cyhoeddwyd

     Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

     Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Meh 2004, Yn: Pharmacogenetics. 14, 6, t. 335-342

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

160. Cyhoeddwyd

     Patient compliance and persistence with prescribed medication: Measurement and health economic impact

     Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 Mai 2004.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

161. Cyhoeddwyd

     Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

     Hughes, D. & Hughes, D. A., 1 Ebr 2004.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

162. Cyhoeddwyd

     Pharmacoeconomics of pharmacogenetic testing: azathioprine

     Hughes, D., McAllister, R. & Hughes, D. A., 1 Ebr 2004.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

163. Cyhoeddwyd

     Approaches to pharmacoeconomic analysis

     Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 101-126

     Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

164. Cyhoeddwyd

     Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

     Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

165. Cyhoeddwyd

     Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

     Hughes, D., Hughes, D. A. & Dubois, D., 1 Ion 2004, Yn: Pharmacoeconomics. 22, 16, t. 1047-1059

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

166. Cyhoeddwyd

     Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Belgium.

     Hughes, D. & Hughes, D. A., 1 Ion 2004, 2004 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

167. Cyhoeddwyd

     Modelling in health economics

     Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 141-154

     Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

168. Cyhoeddwyd

     The future challenges

     Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174

     Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

169. 2003
170. Cyhoeddwyd

     Drug compliance and pharmaceconomics

     Hughes, D. & Hughes, D. A., 1 Rhag 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

171. Cyhoeddwyd

     Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

     Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

172. Cyhoeddwyd

     Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

     Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

173. Cyhoeddwyd

     Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease

     Hughes, D., Hughes, D. A. & Dubois, D., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 613

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

174. Cyhoeddwyd

     Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

     Hughes, D. & Hughes, D. A., 1 Tach 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

175. Cyhoeddwyd

     Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

     Hughes, D. & Hughes, D. A., 1 Tach 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

176. Cyhoeddwyd

     Use of PK-PD modelling to predict the impact of non-compliance

     Hughes, D. & Hughes, D. A., 1 Tach 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

177. Cyhoeddwyd

     Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

     Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

178. Cyhoeddwyd

     Modelling changes in first line antimalarial therapy

     Hughes, D. & Hughes, D. A., 1 Medi 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

179. Cyhoeddwyd

     Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

     Hughes, D., Hughes, D. A. & Walley, T., 1 Gorff 2003, Yn: Clinical Pharmacology and Therapeutics. 74, 1, t. 1-8

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

180. Cyhoeddwyd

     Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

     Hughes, D. & Hughes, D. A., 1 Meh 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

181. Cyhoeddwyd

     Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

     Hughes, D. & Hughes, D. A., 1 Mai 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

182. 2002
183. Cyhoeddwyd

     Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

     Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

184. Cyhoeddwyd

     Economic evaluation during early (phase II) trials

     Hughes, D. & Hughes, D. A., 1 Tach 2002.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

185. Cyhoeddwyd

     Impact of non-compliance on the cost-effectiveness of pharmaceuticals

     Hughes, D. & Hughes, D. A., 1 Tach 2002.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

186. Cyhoeddwyd

     Patient compliance and pharmacoeconomics

     Hughes, D. & Hughes, D. A., 1 Tach 2002.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

187. Cyhoeddwyd

     The population pharmacokinetics of lapdap

     Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Tach 2002.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

188. Cyhoeddwyd

     Economic impact of poor compliance with pharmaceuticals.

     Hughes, D. & Hughes, D. A., 1 Awst 2002, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, t. 327-335

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

189. Cyhoeddwyd

     From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

     Hughes, D. & Hughes, D. A., 1 Mai 2002.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

190. Cyhoeddwyd

     Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

     Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

191. Cyhoeddwyd

     Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

     Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

192. 2001
193. Cyhoeddwyd

     Impact of non-compliance on the clinical and cost-effectiveness of statins

     Hughes, D. & Hughes, D. A., 1 Tach 2001.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

194. Cyhoeddwyd

     Patient compliance and pharmacoeconomics

     Hughes, D. & Hughes, D. A., 1 Hyd 2001.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

195. Cyhoeddwyd

     The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

     Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Hyd 2001, Yn: Health Economics. 10, 7, t. 601-615

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

196. Cyhoeddwyd

     Impact of non-compliance on the cost-effectiveness of statin therapy

     Hughes, D., Hughes, D. A. & Bagust, A., 1 Medi 2001, Yn: Value in Health. 4, 6, t. 489

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

197. Cyhoeddwyd

     Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

     Hughes, D., Hughes, D. A. & Walley, T., 1 Medi 2001.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

198. Cyhoeddwyd

     A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

     Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

199. Cyhoeddwyd

     Accounting for non-compliance in pharmacoeconomic evaluations.

     Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 12, t. 1185-1197

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

200. Cyhoeddwyd

     Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

     Hughes, D., Hughes, D. A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 11, t. 1069-1077

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

201. Cyhoeddwyd

     Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

     Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

202. Cyhoeddwyd

     The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

     Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

203. 2000
204. Cyhoeddwyd

     The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

     Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Tach 2000.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

205. Cyhoeddwyd

     Pragmatic trials - design features and implications for clinical decision making

     Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Awst 2000.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

206. Cyhoeddwyd

     The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

     Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2000, Yn: Value in Health. 3, 5, t. 373

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid